NCT01857232View on ClinicalTrials.gov

Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

PHASE2CompletedINTERVENTIONAL

Enrollment

342

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

CINV

Interventions

DRUG

Ondansetron

5HT3-antagonist

DRUG

Placebo

Comparator

DRUG

Dexamethasone

Corticosteroid

DRUG

Fosaprepitant

NK1 antagonist

DRUG

APD403 IV

Amisulpride IV 20 mg

DRUG

APD403 oral

Amisulpride oral 10, 20 or 40 mg

Trial Locations (1)

Unknown

Odense University Hospital, Odense

Sponsors

Lead Sponsor

Acacia Pharma Ltd

All Listed Sponsors

lead

Acacia Pharma Ltd

INDUSTRY